You are incorrect, it's nowhere near $0.70...read the press release. The cash per share is $0.45 (after paying $13m to Merck). However I listened to the entire Conference Call and Management truly believes in BRINAVESS' potential and they are moving forward to realize it. Btw, they also state they have enough cash for two more years. So hopefully with making inroads getting the approval of the FDA, and by building up enough sales to hospitals, etc. the stock IMHO should run to a minimun of $4.00-$5.00 level before any consideration of shareholder dilution is even menitioned by the BOD .